Biopharmaceutical company developing treatments for neuropsychiatric and neurologic disorders.
Intra-Cellular Therapies, Inc. is a pioneering biopharmaceutical firm focused on advancing novel treatments for neuropsychiatric and neurologic diseases through targeted intracellular signaling mechanisms within the central nervous system. Based in the United States, the company has established itself as a leader in developing innovative therapies that address critical unmet medical needs.
The cornerstone of Intra-Cellular Therapies' portfolio is CAPLYTA, an approved medication for the treatment of schizophrenia in adults. Beyond CAPLYTA, the company is actively involved in the development of lumateperone, currently undergoing Phase III clinical trials for bipolar depression, and exploring its potential applications in treating autism spectrum disorder and other neuropsychiatric indications, including sleep disorders associated with neurological conditions.
In addition to its primary focus on schizophrenia and bipolar disorder, Intra-Cellular Therapies is advancing several promising candidates. These include Lenrispodun (ITI-214), under development for Parkinson's disease and heart failure, ITI-1284-ODT-SL for neuropsychiatric disorders and behavioral disturbances in dementia, and ITI-333 targeting substance use disorders, pain management, and psychiatric comorbidities such as depression and anxiety.
Founded in 2002 and headquartered in New York, New York, Intra-Cellular Therapies continues to drive innovation in neuropsychiatric treatments. Through robust research and development efforts, strategic partnerships, and a commitment to scientific excellence, the company aims to improve the lives of patients worldwide affected by challenging and complex neurological disorders.